Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT
P/B
Price to Book Value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
Market Cap | P/B | ||||
---|---|---|---|---|---|
US |
Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT
|
730m USD | 2.6 | ||
US |
Abbvie Inc
NYSE:ABBV
|
283.3B USD | 27.3 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
164.8B USD | 32.8 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.9B USD | 6.1 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.3B USD | 3.9 | ||
AU |
CSL Ltd
ASX:CSL
|
135.1B AUD | 5.2 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
80.9B USD | 4.6 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
46.7B USD | 3.6 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 16.9 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32B USD | 2.1 | ||
KR |
Celltrion Inc
KRX:068270
|
40.3T KRW | 2.4 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.